Még nem toboroz
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· 3. fázis· Hansoh BioMedical R&D Company· Forrás
Contact: Ding Ma, PhD
Toboroz
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07876557· 2. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Contact: Guohui Han, Ph.D.
Toboroz
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· 3. fázis· Antengene Biologics Limited· Forrás
Contact: Jinfeng Ma
Toboroz
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Contact: Qing Yan
Toboroz
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830· 2. fázis· Tianjin Medical University Cancer Institute and Hospital· Forrás
Contact: Jianzhong Cao
Toboroz
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
NCT07640295· 1/2. fázis· Jacobio Pharmaceuticals Co., Ltd.· Forrás
Contact: ShanXi Cancer Hospital
Toboroz
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Contact: Wei Guo (principal investigator)
Toboroz
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
NCT07689851· 2. fázis· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Forrás
Contact: Jing Jin, M.D.
Toboroz
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
NCT07604766· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602· 2. fázis· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Forrás
Még nem toboroz
Treatment of Recurrent/Metastatic Head and Neck Cancer
NCT07601204· 1/2. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Ruyuan Guo, Master
Toboroz
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· 1. fázis· Shanghai Henlius Biotech· Forrás
Contact: Yinping Zhong
Még nem toboroz
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
NCT07486648· 1/2. fázis· Shanxi Province Cancer Hospital· Forrás
Contact: Jinfang Zhai
Toboroz
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
NCT07462143· 2/3. fázis· RemeGen Co., Ltd.· Forrás
Contact: Hongfang Li
Toboroz
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· 3. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Wenhui Yang, Doctor
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· 3. fázis· RemeGen Co., Ltd.· Forrás
Contact: Yongfeng Yang
Toboroz
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Jianghua Wei, Master
Toboroz
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Hongwei Li, Site 0542
Toboroz
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529· 1/2. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Xin Wang, Doctor
Fut, nem toboroz
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923· 1. fázis· Hansoh BioMedical R&D Company· Forrás
Toboroz
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236· 2. fázis· Fujian Cancer Hospital· Forrás
Contact: Qin Xu, Ph.D
Toboroz
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· 3. fázis· Pfizer· Forrás
Toboroz
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· 3. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Contact: Hongxia Lu, Doctor
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Contact: Clinical Trials
Toboroz
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822· 2. fázis· Peking University· Forrás
Contact: Hongxia Lu
Fut, nem toboroz
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
NCT07162883· 3. fázis· Qilu Pharmaceutical Co., Ltd.· Forrás
Toboroz
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245· 2. fázis· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Forrás
Contact: Qingxian Huang
Toboroz
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: wei guo, Site 0258
Toboroz
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Guohui Han, Site 1018
Toboroz
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994· 1/2. fázis· MediLink Therapeutics (Suzhou) Co., Ltd.· Forrás
Contact: Study Coordinator
Toboroz
A Study of SKB518 in Patients With Lung Cancer
NCT07019675· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Contact: Qinxiang Guo
Toboroz
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679· 2/3. fázis· Beijing Biostar Pharmaceuticals Co., Ltd.· Forrás
Contact: Wenhui Yang (principal investigator)
Toboroz
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650· 1/2. fázis· Dizal Pharmaceuticals· Forrás
Contact: Su
Toboroz
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936· 1/2. fázis· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Forrás
Contact: Meiping Kong
Toboroz
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Guohui Han, Master
Toboroz
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· 3. fázis· Evopoint Biosciences Inc.· Forrás
Contact: Yingjie zhao
Toboroz
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865· 2. fázis· RemeGen Co., Ltd.· Forrás
Contact: Heping Liu
Toboroz
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Guohui Han, Master
Toboroz
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· 2. fázis· Abbisko Therapeutics Co, Ltd· Forrás
Contact: Jinfeng Ma
Toboroz
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· 3. fázis· Akeso· Forrás
Contact: Hongwei Li, M.D.
Toboroz
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás
Contact: Jianchun Duan, Site 0353
Toboroz
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771· 1/2. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Liping Su, Doctor
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996· Daiichi Sankyo· Forrás
Contact: Principal Investigator
Toboroz
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· 3. fázis· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Forrás
Contact: Guohui Han
Toboroz
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324· 3. fázis· Nuvation Bio Inc.· Forrás
Contact: Wei Guo
Toboroz
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615· 1/2. fázis· Jacobio Pharmaceuticals Co., Ltd.· Forrás
Contact: Jacobio Pharmaceuticals
Toboroz
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· 3. fázis· Shanghai Henlius Biotech· Forrás
Contact: Ying Li
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: wei guo, Site 0435
Showing 50 of 81.